Asprosin aggravates atherosclerosis via regulating the phenotype transformation of vascular smooth muscle cells
Copyright © 2024. Published by Elsevier B.V..
Phenotype transformation of vascular smooth muscle cells (VSMCs) plays an important role in the development of atherosclerosis. Asprosin is a newly discovered adipokine, which is critical in regulating metabolism. However, the relationship between asprosin and phenotype transformation of VSMCs in atherosclerosis remains unclear. The aim of this study is to investigate whether asprosin affects the progression of atherosclerosis by inducing phenotype transformation of VSMCs. We established an atherosclerosis model in ApoE-/- mice and administered asprosin recombinant protein and asprosin antibody to mice. Knocking down asprosin was also as an intervention. Interestingly, we found a correlation between asprosin levels and atherosclerosis. Asprosin promoted plaque formation and phenotype transformation of VSMCs. While, AspKD or asprosin antibody reduced the plaque lesion and suppressed vascular stiffness in ApoE-/- mice. Mechanistically, asprosin induced phenotype transformation of MOVAs by binding to GPR54, leading to Gαq/11 recruitment and activation of the PLC-PKC-ERK1/2-STAT3 signaling pathway. Si GPR54 or GPR54 antagonist partially inhibited the action of asprosin in MOVAs. Mutant GPR54-(267, 307) residue cancelled the binding of asprosin and GPR54. In summary, this study confirmed asprosin activated GPR54/Gαq/11-dependent ERK1/2-STAT3 signaling pathway, thereby promoting VSMCs phenotype transformation and aggravating atherosclerosis, thus providing a new target for the treatment of atherosclerosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:268 |
|---|---|
| Enthalten in: |
International journal of biological macromolecules - 268(2024), Pt 2 vom: 25. Apr., Seite 131868 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhao, Yu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Asprosin |
|---|
| Anmerkungen: |
Date Revised 01.05.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.ijbiomac.2024.131868 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371665329 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371665329 | ||
| 003 | DE-627 | ||
| 005 | 20240503000809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240428s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijbiomac.2024.131868 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1395.xml |
| 035 | |a (DE-627)NLM371665329 | ||
| 035 | |a (NLM)38677690 | ||
| 035 | |a (PII)S0141-8130(24)02673-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhao, Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Asprosin aggravates atherosclerosis via regulating the phenotype transformation of vascular smooth muscle cells |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.05.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024. Published by Elsevier B.V. | ||
| 520 | |a Phenotype transformation of vascular smooth muscle cells (VSMCs) plays an important role in the development of atherosclerosis. Asprosin is a newly discovered adipokine, which is critical in regulating metabolism. However, the relationship between asprosin and phenotype transformation of VSMCs in atherosclerosis remains unclear. The aim of this study is to investigate whether asprosin affects the progression of atherosclerosis by inducing phenotype transformation of VSMCs. We established an atherosclerosis model in ApoE-/- mice and administered asprosin recombinant protein and asprosin antibody to mice. Knocking down asprosin was also as an intervention. Interestingly, we found a correlation between asprosin levels and atherosclerosis. Asprosin promoted plaque formation and phenotype transformation of VSMCs. While, AspKD or asprosin antibody reduced the plaque lesion and suppressed vascular stiffness in ApoE-/- mice. Mechanistically, asprosin induced phenotype transformation of MOVAs by binding to GPR54, leading to Gαq/11 recruitment and activation of the PLC-PKC-ERK1/2-STAT3 signaling pathway. Si GPR54 or GPR54 antagonist partially inhibited the action of asprosin in MOVAs. Mutant GPR54-(267, 307) residue cancelled the binding of asprosin and GPR54. In summary, this study confirmed asprosin activated GPR54/Gαq/11-dependent ERK1/2-STAT3 signaling pathway, thereby promoting VSMCs phenotype transformation and aggravating atherosclerosis, thus providing a new target for the treatment of atherosclerosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Asprosin | |
| 650 | 4 | |a Atherosclerosis | |
| 650 | 4 | |a GPR54 signaling | |
| 650 | 4 | |a VSMCs phenotype transformation | |
| 700 | 1 | |a Wang, Zhengkai |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Min |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xinxin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Huan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Nannan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhiqi |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Shifeng |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yixiu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of biological macromolecules |d 1992 |g 268(2024), Pt 2 vom: 25. Apr., Seite 131868 |w (DE-627)NLM012627356 |x 1879-0003 |7 nnns |
| 773 | 1 | 8 | |g volume:268 |g year:2024 |g number:Pt 2 |g day:25 |g month:04 |g pages:131868 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijbiomac.2024.131868 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 268 |j 2024 |e Pt 2 |b 25 |c 04 |h 131868 | ||